Staar Surgical kommt ganz still und heimlich! Wer ist dabei? - 500 Beiträge pro Seite

eröffnet am 04.09.00 13:35:55 von
neuester Beitrag 25.08.08 04:13:02 von


Beitrag schreiben

Begriffe und/oder Benutzer

 

Avatar
04.09.00 13:35:55
So langsam wird es Zeit auch mal Staar Surgical (STAA; WKN: 870353) hier im board zu erwähnen.
Wer eine Sehhilfe hat oder benötigt, sollte sich dieses Unternehmen mal näher anschauen!!!!!
Bereits seit längerer Zeit zwar dem Trend entsprechend, aber dennoch im ruhigeren Fahrwasser steigt STAA langsam an eine entscheidende, charttechnische Marke.
Alle "medical strategy" Leser kennen diesen Wert bereits. (Insofern Interesse besteht kann ich gerne diesen Wert näher beschreiben).
Einmal einen Thread zu eröffnen, der sich nicht nur rein um Gene handelt, sondern eine Materie darstellt, die leicht verständlich ist, war hiermit mein Ziel.
WER IST DRIN?
WER INTERESSIERT SICH FÜR DIESEN WERT?
- schreibt was rein!!!!!!!!

Gruß
winetrader
Avatar
04.09.00 14:31:21
Kennst du das Gefühl, wenn man am Bahnhof steht und der Zug
ist abgefahren??

Ich hoffe du verstehst, was ich meine
Avatar
04.09.00 14:36:11
Natürlich Interessiere ich mich dafür kann nur keine Infos finden
bitte schreib doch mal genaueres
Grüsse
CK
Avatar
04.09.00 14:41:28
Natürlich Interessiert man sich für solche Werte,
finde aber keine Infos hier
schreib doch bitte mal genaueres
grüsse
CK
Avatar
04.09.00 19:28:37
Was macht Staar Surgical:
STAA entwickelt medizintechnische Produkte für den Augenbereich.
Im Moment hat STAA eine faltbare Intraokularlinse, IOL, (Behandlung bei Linsentrübung) auf dem Markt mit einem Jahresumsatz von 55 Mio US$.
Eine zweite Linse, die implantierbare Kontaktlinse, ICL, eine Weiterentwicklung, ist in der Entwicklung wird oder wurde bereits zur Zulassung bei der FDA angemeldet. Die zulassung wird Ende des Jahres erwartet. Diese Linsenart ist die bessere Alternative zum Lasern.
Nachteile beim Lasern:
- Augengewebe wird zerstört
- Eingriff ist nicht reversibel
- Korrekturen nach der Op. nicht mehr möglich
Vorteile dieser neuartigen Linse:
+ 15 minütige ambulante Behandlung mit lediglich lokaler Betäubung wird diese Linse ins Auge eingepflanzt. (kann bei fast jedem Augenarzt gemacht werden; keine große techn. Investition notwendig)
+ bei Kurz- und Weitsichtigkeit möglich (weltweit bei 50% betroffener Bevölkerung ein ca. 25 Mrd.US$ schwerer Markt)
+ kürzere Heilungszeit gegenüber Laser
+ Linse kann wieder entfernt und durch andere Sehstärke ersetzt werden
Die ICL ist bereits Südamerika und Südafrika auf dem Markt.
Das dritte und zukunftsträchtige Produkt ist AQUA FLOW.
Es besteht aus einem kleinen Collagendocht, der ins Auge implantiert wird, sich langsam auflöst und einen natürliche Abflusskanal des Kammerwassers zurückläßt.
AQUA FLOW dient zur Behandlung des Glaukoms (zur Erblindungführender Augenhochdruck). Bishereige verfügbare Behandlungsmethoden waren begrentzt. Allein über 2 Mio Amis haben dieses Augenleiden.
Auch diese Behabdlung ist, obwohl es sich schlimm anhört, ambulant möglich!
STAAR SURGICAL will ausgehend von 50 Mio. Umsatz in 1999 in den nächsten fünf Jahren auf 250 Mio. Umsatz zulegen.
In Anbetracht, was bei STAA in der absehbaren Pipeline steckt, ist der Wert meines Erachtens kurz vor dem Sprung.

winetrader
Avatar
06.09.00 17:51:47
Scheinbar aufgrund, daß es sich bei STAA nicht um Genarbeiten handelt, ist das Interesse eingeschränkt.
Dennoch halte diesen thread aktuell.
Deshalb:

Press Release
SOURCE: STAAR Surgical Company
STAAR Surgical`s Toric(TM) Lens Sales Accelerate Sharply
MONROVIA, Calif., Sept. 6 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA - news) announced today that sales of its Toric(TM) intraocular lens (IOL) have improved significantly. ``Sales of the Toric(TM) IOL have risen sharply,`` stated Robert A. Kenz, VP of Domestic Sales, ``with average weekly sales rising from just over $45,000 in July, to well over $76,000 in August.``

``We`re also experiencing a strong increase in sales of our Collamer(TM) IOL,`` continued Mr. Kenz. ``Average weekly sales were $83,000 in July, and that figure has accelerated to over $105,000 in August. We continue to expect manufacturing approval in Monrovia for the one-piece Collamer(TM) IOL sometime this month, with three-piece manufacturing approval coming by year-end. Given the industry dominance of three-piece lenses, we expect the three-piece Collamer(TM) IOL to contribute significantly to sales once it becomes commercially available.``

``Based on recent trends,`` added Mr. Andrew F. Pollet, Chairman, ``we feel very confident in our business and its ability to provide upside potential as the year progresses. Sales in the U.S. and Canada have been at record levels for the last seven weeks, led by strong sequential increases in sales of our Collamer(TM) and Toric(TM) IOLs. The strong increase in sales, particularly at a seasonally slow period when doctors and patients are still on vacation, shows the successful impact on market penetration that our salesforce is having, as well as the overall market acceptance of these one-of-a-kind products.``

``Internationally, the continued strength of the dollar versus the Deutsche Mark will have an impact on our business if the exchange rate continues at its current, record level. We will continue to monitor the situation closely,`` concluded Mr. Pollet, ``although exchange rates are obviously out of our direct control.``

Founded in 1982, STAAR Surgical Company develops, manufactures and globally distributes minimally invasive medical devices for use in refractive, cataract and glaucoma surgery. The Company`s principle product lines include foldable intraocular lenses, which are used as replacements for the natural lens in cataract procedures. STAAR Surgical also markets two new products internationally: the Implantable Contact Lens(TM), which is a refractive lens for the treatment of nearsightedness and farsightedness, and the AQUA-FLOW(TM) collagen glaucoma drainage device. All of the company`s products, except for the Toric ICL(TM), have received CE Marking for distribution in the European Union.

For additional information, visit the Company`s web site at: http://www.staar.com, or call Richard Leza, VP Business Development and Corporate Strategy, at (626) 303-7902, ext. 2202.

Certain statements in this press release constitute ``forward-looking statements`` within the meaning of Sections 21E and 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. All forward-looking statements involve risks and uncertainties that may cause the Company`s actual results to be materially different. Factors that could impact the Company`s future results are set forth in the cautionary statements included in Exhibit 99 to the Company`s Form 10-Q dated March 30, 2000, filed with the Securities and Exchange Commission.

SOURCE: STAAR Surgical Company
Avatar
07.09.00 15:27:35
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Avatar
29.09.00 20:59:22
Hallo Winetrader

Wie ich gelesen hab, hast Du auch das Abo von Medical Strategy.

Ich hab den Brief seit der Septemberausgabe.

1. Welche Werte hast Du Dir dort rausgesucht?
2. Wann kommt der Brief eigentlich? Immer Ende des Monats?

Ich hab mir die Aradigm, Aviron, Enzon, Lifecell, Osi und Vidamed rausgesucht und gekauft.

Wird in dem Brief eigentlich jeden Monat eine Aktie besonders vorgestellt, wie diesmal Vidamed?

Mitch
Avatar
30.09.00 12:28:31
@ mitch oder @ winetrader:
wo kann ich genauere infos über den biotechbrief medical strategy bekommen?? ist das die firma, die auch den lacuna biotechfond berät??
bitte mailt mir doch kurz (oder postet hier):
abstraktionist@gmx.de
Avatar
30.09.00 18:16:06
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Avatar
02.10.00 08:09:13
Friday September 29, 8:55 am Eastern Time
Press Release
SOURCE: STAAR Surgical Company
STAAR Surgical`s AquaFlow(TM) Scheduled for November 8th Panel Meeting
MONROVIA, Calif., Sept. 29 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA - news) announced today that it has been notified that the U.S. Food and Drug Administration`s (FDA) Ophthalmic Device Panel (ODP) will review the company`s pre-market approval (PMA) application for the AquaFlow(TM) glaucoma device on November 8, 2000. Made of pure, natural collagen, the AquaFlow(TM) glaucoma device is used as part of a lower-risk, non-penetrating surgical procedure that has gained increased attention over the last several months.

``We look forward to reporting the results of our clinical trial to the ODP,`` said Steven L. Ziemba, Sr. VP of Regulatory Affairs. ``Our data appears to indicate that use of the AquaFlow(TM) facilitates a simpler surgical procedure that can provide long-lasting reduction in intraocular pressure, comparable to current surgeries, but with fewer complications and a significant reduction in the need for medications.``

``We are pleased to announce this significant milestone,`` added Andrew F. Pollet, Chairman. ``We believe the AquaFlow(TM) glaucoma device represents a safer, less-invasive alternative to existing laser and conventional surgeries. By providing long-term maintenance of intraocular pressure, we believe AquaFlow(TM) has the ability to change the paradigm for glaucoma treatment by offering the patient long-lasting reduction of intraocular pressure, with greater independence from costly medications.``

Glaucoma is generally caused by a build-up in intraocular pressure within the eye, which can lead to damage of the optic nerve and the gradual loss of sight. Left untreated, it can lead to blindness. Glaucoma impacts people of any age, sex, or race, and there is no known cure. With an estimated 4 million people afflicted in the U.S. alone, and another 100,000 new cases diagnosed annually, glaucoma imposes significant social and economic costs on Americans.

Founded in 1982, STAAR Surgical Company develops, manufactures and globally distributes minimally invasive medical devices for use in cataract, refractive and glaucoma surgery. The Company`s principle product lines include foldable intraocular lenses, which are used as replacements for the natural lens in cataract procedures. STAAR Surgical also markets two new products internationally: the Implantable Contact Lens(TM), which is a refractive lens for the treatment of nearsightedness and farsightedness, and the AquaFlow(TM) glaucoma device. All of the company`s products, except for the Toric ICL(TM), have received CE Marking for distribution in the European Union.

For additional information, visit the Company`s web site at: http://www.staar.com , or call Richard Leza, VP Business Development and Corporate Strategy, at (626) 303-7902, ext. 2202.

Certain statements in this press release constitute ``forward-looking statements`` within the meaning of Sections 21E and 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. All forward-looking statements involve risks and uncertainties that may cause the Company`s actual results to be materially different. Factors that could impact the Company`s future results are set forth in the cautionary statements included in Exhibit 99 to the Company`s Form 10-Q dated June 30, 2000, filed with the Securities and Exchange Commission.

SOURCE: STAAR Surgical Company
Avatar
06.10.00 12:05:50
Das private placement über eine Summe von 21 Mio., welches das Unternehmen stärken wird, ist gut abgeschlossen worden ohne daß die Aktie sonderlich gelitten hat. Dies beweist auch, daß große Anleger Vertrauen dem Unternehmen entgegen bringen.
AQUAFLOW und die allgemeine Entwicklung von STAA wird auch in nächster Zeit für positive news sorgen.
Man darf sich zurücklehnen und beruhigt zuschauen wie sich dieser Wert sehr gut entwickeln wird.

Gruß
winetrader
Avatar
11.10.00 08:27:28
Und weiter geht`s bei STAA:

STAAR Surgical Receives One-Piece Collamer(TM) Manufacturing Clearance
MONROVIA, Calif., Oct. 9 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA - news) announced today that it has received GMP (Good Manufacturing Practices) approval from the U.S. Food and Drug Administration (FDA) to begin manufacturing the one-piece Collamer(TM) intraocular lens (IOL) in Monrovia.

``This is an extremely important step for us,`` stated Steven L. Ziemba, Sr. VP of Regulatory Affairs. ``Now that we have received approval to make Collamer(TM) lenses in Monrovia, we will immediately work towards manufacturing clearance of the three-piece Collamer(TM) lens. Although the single-piece Collamer(TM) has been received with tremendous enthusiasm in the ophthalmic community, some surgeons are waiting for a three-piece version of this lens. Now we can proceed quickly towards introduction of that design.``

``GMP approval,`` added Andrew F. Pollet, Chairman, ``is a standard for the manufacture and documentation of medicinal products that provides assurance that the product manufactured is of consistent quality to known standards. All of the products we manufacture are of the highest-quality and exceed governmental standards. As a result, this clearance was received with no additional plant inspection.``

The Collamer(TM) IOL is made from a unique, proprietary, biocompatible material developed by STAAR Surgical. The lens, which received FDA approval in April 2000, is made with the same material used in the Company`s Implantable Contact Lens(TM) (ICL(TM)).

Founded in 1982, STAAR Surgical Company develops, manufactures and globally distributes minimally invasive medical devices for use in cataract, refractive and glaucoma surgery. The Company`s principle product lines include foldable intraocular lenses, which are used as replacements for the natural lens in cataract procedures. STAAR Surgical also markets two new products internationally: the Implantable Contact Lens(TM), which is a refractive lens for the treatment of nearsightedness and farsightedness, and the AquaFlow(TM) glaucoma device. All of the company`s products, except for the Toric ICL(TM), have received CE Marking for distribution in the European Union.

For additional information, visit the Company`s web site at: http://www.staar.com, or call Richard Leza, VP Business Development and Corporate Strategy, at (626) 303-7902, ext. 2202.

Certain statements in this press release constitute ``forward-looking statements`` within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on expectations as of the date of a particular release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in STAAR Surgical Company`s reports filed with the Securities and Exchange Commission.

SOURCE: STAAR Surgical Company
Avatar
27.11.00 18:16:40
Und weiter gehts:
(akuelle Marktkap.: ca. 200 Mio US$)


STAAR Ships First Three-Piece Collamer IOLs

Three-Piece Collamer IOL Offers Significant Revenue Opportunity For STAAR in a $450 to $500 Million International IOL Marketplace

MONROVIA, Calif., Nov. 27 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA - news) announced today that shipment of the Company`s newest product, the three-piece Collamer IOL has begun. STAAR began shipments of the single-piece Collamer IOL in April, 2000. This product, made entirely in a new, state-of-the-art cleanroom environment at the Company`s Monrovia, CA facility, gives STAAR the opportunity to expand its non-silicone foldable lens products into a new, robust market segment. Many ophthalmic surgeons prefer the surgical flexibility that three-piece intraocular lenses offer, and the market is moving towards non-silicone foldable lenses. The three-piece collamer IOL, which rests in the eye in a different fashion than the one-piece model, requires a less complicated approach to surgery. Full market release of the product is scheduled for January 2001.

``This is a significant milestone for STAAR not only because it expands our market for the Collamer product, but also because it marks the complete phase-in of our new production area in Monrovia,`` said Michael L. Chandler, STAAR`s Vice-President of Operations. Mr. Chandler added, ``In less than twelve months, we built an entirely new `facility within a facility` for this product, and obtained FDA approval for it. The new area incorporates the latest in lathe-cut lens technology while utilizing as much of STAAR`s existing systems as possible. That way, we were able to put out an extremely innovative product in the most cost-efficient manner.``

``Our shareholders ought to be very proud of Mr. Chandler and his staff,`` said Andrew F. Pollet, Chairman and Interim CEO of STAAR. ``Once again, we promised new product and our team actually beat the deadline.`` Mr. Pollet further commented, ``Due to the overwhelming popularity of three-piece intraocular lenses, we believe STAAR has a significant opportunity to increase revenues. Currently, plate haptic lenses (one-piece) have a ten-percent market share. This new, three-piece version allows STAAR to use the new Collamer lens to improve its competitive position for the remaining ninety-percent of an industry estimated to be $450 to $500 million worldwide.``

About STAAR Surgical

Founded in 1982, STAAR Surgical Company develops, manufactures and globally distributes minimally invasive medical devices for use in cataract, refractive and glaucoma surgery. The Company`s principle product lines include foldable intraocular lenses, which are used as replacements for the natural lens in cataract procedures. STAAR Surgical also markets two new products internationally: the Implantable Contact Lens(TM), which is a refractive lens for the treatment of nearsightedness and farsightedness, and the AquaFlow(TM) glaucoma device. All of the company`s products, except for the Toric ICL(TM) and the Sonic Wave, have received CE Marking for distribution in the European Union. For additional information, visit the Company`s web site at http://www.staar.com.

Certain statements in this press release constitute ``forward-looking statements`` within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on expectations as of the date of a particular release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in STAAR Surgical Company`s reports filed with the Securities and Exchange Commission.
Avatar
27.11.00 19:07:22
Hallo Winetrader !

Kannst du mir mal verraten, wo ich eine Chartübersicht
von STAAR bekomme !?!

Und welches KZ ist hier auf 1-2 Jahren zu erwarten ?
Avatar
27.11.00 21:03:48
Hallo schwabday,

bei www.yahoo.com wirst du charts zu STAA finden.

Nähere Infos auch unter www.staar.com

Kursziel liegt bei 35 US$ auf 12-24 Monate.

winetrader
Avatar
24.01.01 19:59:57
Die Experten des Börsenmagazins "Der Aktionär" empfehlen risikoorientierten Anlegern das aktuelle Kursniveau von STAAR Surgical zum Einstieg und zum Aufbau langfristiger Positionen zu nutzen.

Das US-Unternehmen biete Lösungen für die Behandlung der häufigsten zeitgenössischen Augenerkrankungen. Es habe sich auf die Entwicklung, Produktion und Vermarktung medizinischer Geräte auf dem Gebiet der Augenheilkunde spezialisiert. Die Besonderheit der STAAR-Produkte liege darin, dass sie für einen minimaleninvasiven Eingriff konzipiert seien.

Die Experten erwarten nach 59 Mio. US-Dollar im Jahr 1999 für das jüngst zu Ende gegangene Geschäftsjahr 2000 eine Umsatzsteigerung auf mindestens 88,2 Mio. US-Dollar. Der Gewinn je Aktie werde voraussichtlich bei 6 Cents liegen. Für das laufende Geschäftsjahr 2001 prognostiziert "Der Aktionär" ein weiteres deutliches Umsatzwachstum auf knapp 105 Mio. US-Dollar. Der Gewinn je Aktie solle dann im Bereich von 42 Cents liegen.

Im Segment der Hersteller medizinischer Geräte zur Behandlung von Augenkrankheiten sei STAAR Surgical hervorragend positioniert. Bei einer derzeitigen Marktkapitalisierung von knapp 190 Mio. US-Dollar sei das Unternehmen jetzt noch äußerst günstig bewertet. Die Aktie eigne sich als spekulative Depotbeimischung für risikoorientierte Anleger.

Analyst: Der Aktionär
WKN der Aktie: 870353
KGV 01e: k.A.
Besprechungskurs: 11,43 US-Dollar
Kursziel: 18 US-Dollar
Rating des Analysten: spekulative Depotbeimischung

Quelle: Aktienresearch 18.01.2001 12:56
Avatar
26.03.01 16:56:54
@ all

Was ist los bei Staar??? Wieso ist der Wert so abgestürzt?? Fischer hat die Aktien vorigen Monat ins sein Musterdepot nachgekauft, hat er sich da gewaltig geirrt? Hab ich irendwas verpasst?


Gruß Predo
Avatar
26.03.01 19:14:00
Tuesday March 20, 5:03 pm Eastern Time
STAAR Surgical has Q4 loss, sees fiscal 2001 break-even
MONROVIA, Calif., March 20 (Reuters) - STAAR Surgical Co. (NasdaqNM:STAA - news), a maker of medical devices for the eye, on Tuesday reported a fourth quarter net loss and warned that earnings for its fiscal 2001 would fall short due to slower market growth.

For fourth quarter 2000, the company reported a net loss of $1.2 million, or 7 cents a share, on revenues of $13.7 million, compared with net income of $277,000, or 2 cents share, on revenues of $15.8 million for last year`s fourth quarter.

The company cited adverse exchange rates and higher marketing costs for the fourth quarter results. Also during the fourth quarter, the company took a charge of $1.5 million to establish a reserve against a receivable note to previous president and chairman John R. Wolf.

For fiscal 2001, the company said it expects to report break-even results on approximately $55 million in sales, compared with the First Call estimate of a 42-cent-per-share profit. The forecast was attributed to eroding market growth for certain products and a slower roll-out for a device used to treat glaucoma patients.
Avatar
02.06.01 22:56:42
Nachdem was der neue Vorsitzende veröffentlicht, war das Management im letzten Jahr fast komplett ausgewechselt wordem. Ein Jahr der Umstrukturierung, die aber, aufgrund der schlechten Verkaufszahlen, gerechtfertigt war. Ja, man muß wohl von Mißmanagement sprechen. Dies wurde bisher nicht im medical erwähnt. die aktuellen Tätigkeiten des neuen Chefs, scheint die Saat für eine deutlich bessere Entwicklung zu sein. Seine Branchenkompetenz scheint im letzten Moment gekommen zu sein.
Der aktuelle stark gebeutelte Kurs sollte man zum Einstieg oder zum Nachkauf nutzen. Im Laufe des Jahres sollte man erkennen können, daß es im Verkauf wieder gegen Norden geht.(trotz starken Dollar und inländischer Konjunkturabschwächung)
Im amerikanischen board wurde der Führungswechsel ebenfalls befürwortet.

winetrader
Avatar
05.06.01 18:15:07
Bin heute eingestiegen!!!

MfG Pieselwitz!!
Avatar
06.06.01 17:57:33
Niemand mehr investiert?????

Schon wieder 10% nach oben und das bei diesem schwachen Umfe3ld!!

MfG Pieselwitz!!
Avatar
18.07.01 08:43:13
So, wenn jetzt noch die Zahlen stimmen, dann geht es sehr schnell wieder gen Norden!
Mißmanagment, welches im Jahr 2000 ausgebügelt wurde, jetzt ein Topmann an der Spitze... die Zahlen können nun nur stetig besser werden!!!!
Deshalb:
Strong Buy!!!

winetrader


Monday July 16, 7:30 am Eastern Time
Press Release
SOURCE: STAAR Surgical Company
STAAR Surgical Receives FDA Approval for AquaFlow(TM)
Shipments to begin immediately
MONROVIA, Calif., July 16 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA - news) announced today that it has received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA) for its AquaFlow(TM) Collagen Glaucoma Drainage Device for use in the correction of open-angle Glaucoma. The Company is prepared to begin shipment of the device immediately. The AquaFlow has been approved and marketed in other countries for several years. In 1997, AquaFlow received CE Mark allowing it to be marketed throughout the European Union. Earlier this year a Medical Device Licensure was received from Health Canada, allowing the marketing of AquaFlow throughout Canada.

According to David Bailey, president and chairman of STAAR Surgical Company, ``We have made a significant investment to prepare for marketing of the AquaFlow upon FDA approval. We have trained over 300 physicians who are now ready to use the AquaFlow and shipments will begin immediately. FDA approval of the AquaFlow is a major milestone for STAAR Surgical as it opens a potential market in the U.S. of approximately $70 million.``

Stephen Bylsma, M.D. of the Shepard Eye Center in Santa Maria, California who is the medical monitor for the AquaFlow said, ``While the traditional trabeculectomy (glaucoma surgery) is very effective, the potential risks are not trivial. With the AquaFlow procedure, we have an effective way to lower intraocular pressure with much lower risks than standard trabeculectomy. This means a quicker return to normal activities for the patient and fewer visits and post-operative procedures for both patient and doctor.``

Bylsma added, ``I have been impressed by the consistent results of the AquaFlow procedure, with patients returning to normal activities much faster than with traditional glaucoma surgery. Most patients have a good lowering of intraocular pressure and remain without the need for eye drops to control their pressure.``

STAAR`s AquaFlow Collagen Glaucoma Drainage Device is implanted as part of a lower risk, non-penetrating surgical procedure for the treatment of glaucoma that helps to significantly reduce pressure in the eye. AquaFlow study patients had very few of the complications often associated with traditional glaucoma surgery. In most cases the AquaFlow surgery eliminates the need for glaucoma medications. Glaucoma is often associated with increased intraocular pressure. Left untreated, this increased pressure can damage the optic nerve resulting in a gradual decline in vision, blind spots and eventual blindness. Affecting roughly 67 million people worldwide, glaucoma is a leading cause of blindness if left untreated. In the U.S., there are an estimated 4 million people afflicted with approximately 100,000 new cases diagnosed each year. The worldwide glaucoma drug market is about $1.4 billion.

Founded in 1982, STAAR Surgical Company develops, manufactures and globally distributes medical devices for use in refractive, cataract and glaucoma surgery. The Company`s five product lines include silicone and Collamer(TM) foldable intraocular lenses and the Sonic WAVE(TM) phacoemulsification system, all of which are used during cataract surgery, the ICL(TM) (implantable contact lens) which is a refractive lens for the treatment of near- and far-sightedness and the AquaFlow(TM) Collagen Glaucoma Drainage Device. Regulatory approvals vary from market to market with all products except the Toric ICL(TM) and the 3-piece Collamer(TM) IOL available in Europe and all except the ICL(TM) in the United States
Avatar
15.05.03 18:34:46
Study Concludes STAAR`s ICL(TM) Is Safer and More Effective Than LASIK
Thursday May 15, 9:20 am ET
Results of Study Published in Cornea


MONROVIA, Calif., May 15 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA - News) a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that the May 2003 edition of Cornea, The Journal of Cornea and External Disease has published the findings of a study comparing the results of laser assisted in situ keratomileusis (LASIK) and implantable contact lenses (ICL).
The article entitled "Comparison of Implantable Contact Lens and Laser Assisted In Situ Keratomileusis for Moderate to High Myopia" authored by Donald R. Sanders, M.D., Ph.D. and John A. Vukich, M.D., concludes that the ICL is safer, more effective and appears to be a viable alternative to LASIK, which utilizes corneal refractive excimer lasers, in the treatment of moderate to high myopia.

In the article, the postoperative results of 210 eyes implanted with the ICL are compared with the postoperative results of 559 eyes on which LASIK surgery was performed. All of the patients were examined at one day, one week, one month, six months and one year postoperatively. The average level of myopia for the ICL patients was minus 9.1 diopters and the LASIK surgery patients had a slightly lower level of myopia at an average of minus 9.8 diopters.

Drs. Sanders and Vukich reported that in every index of BSCVA (Best Spectacle Corrected Visual Acuity), UCVA (Uncorrected Visual Acuity), predictability of refraction and stability of refraction, the ICL outperformed the LASIK procedure. After six months, the study indicated that while seven percent of ICL patients had gained two or more lines on the standard eye chart of BSCVA, only three percent of LASIK surgery patients had gained two or more lines and two percent of LASIK patients had actually lost two or more lines on the chart.

After six months, the predictability of the ICL procedure was much higher with 90% of patients within 1 diopter of attempted correction and 65% within 0.5 diopters. LASIK surgery had statistically significantly less favorable results with only 76% of patients within 1 diopter of attempted correction and 53% within 0.5 diopters after six months. The ICL also scored higher in the UCVA 20/20 or better comparison with 50% of those treated achieving 20/20 vision or better, while 35% of LASIK patients reached this level of visual acuity.

"We are very pleased with the results of this study which are quite encouraging," said David Bailey, president and CEO of STAAR Surgical. "The favorable comparisons between our industry-leading phakic technology and LASIK technology further underscore the radical paradigm shift in refractive surgery that we believe the ICL represents. This study clearly illustrates that the ICL offers patients a more predictable alternative to LASIK."

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR`s products are used by ophthalmic surgeons and include the revolutionary Implantable Contact Lens as well as innovative products designed to improve patient outcomes for cataracts and glaucoma.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products and government approval of new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the need to obtain regulatory approval for new products, acceptance of new products by medical practitioners and consumers, the rapid pace of technological change in the ophthalmic industry, general domestic and international economic conditions, and other factors beyond the control of STAAR Surgical Company, including those detailed from time to time in STAAR Surgical Company`s reports filed with the Securities and Exchange Commission. STAAR Surgical Company assumes no obligation and does not intend to update these forward-looking statements.

CONTACT: investors, Douglas Sherk, +1-415-659-2285, or Jennifer Cohn, +1-415-659-2289, or media, Sheryl Seapy, 415-272-3323, all of EVC Group, for STAAR Surgical Company




--------------------------------------------------------------------------------
Source: STAAR Surgical Company

Avatar
16.05.03 16:58:15
Dow Jones Business News
Staar Surgical`s Shares up After Positive Study on Lenses
Thursday May 15, 1:51 pm ET
By Tiffany Kary


NEW YORK -- A study in ophthalmology journal Cornea had investors seeing clear benefits for Staar Surgical Co. (NasdaqNM:STAA - News) and its implantable contact lenses Thursday.
ADVERTISEMENT


In afternoon trading on the Nasdaq National Market, shares of Staar Surgical rose $1.68, or 17%, to $11.83, as the maker of minimally invasive ophthalmic products touted the journal`s report that its implantable contact lenses, or ICL, are safer and more effective than Lasik eye surgery for correcting myopia, or nearsightedness.

The Monrovia, Calif.-based company, which also makes glaucoma treatments and lenses for cataracts, recently submitted an application to the Food and Drug Administration (News - Websites) for U.S. approval of the lenses, which are inserted into the eye through a small incision. Staar already sells the lenses in international markets, according to a company spokesman.

The spokesman also said international markets make up 54% of the company`s revenue overall, but a small percent of that revenue comes from the lenses.

Adams, Harkness & Hill analyst Ryan Rauch said the study was good news for Staar, as it indicated that the company may now be able to take some of Lasik`s business in the market for mild to medium myopia. Expectations that the company would dominate in the market for severe myopia were already built into the share price, he said.

According to the study, in Cornea`s May issue, the lenses outperformed the Lasik procedure on all measures, and showed that, after six months, 7% of patients with the implanted lenses had gained two or more lines on the standard eye chart, while only 3% of Lasik patients had gained two or more lines.

The study in Cornea was done by two doctors, both of whom are consultants to Staar Surgical, according to Cornea`s Web site.

Mr. Rauch estimates that about 4.5 million people in the U.S. have mild to medium-grade myopia, and 3 million have severe myopia. With the lenses costing $ 500 to $700 each, "it`s a multibillion opportunity," Mr. Rauch said. He added that gross margins for Staar will be around 80%, and that the company is well ahead of its only competitors -- CibaVision, a unit of Novartis AG`s (NVS), and Advanced Medical Optics Inc. (NYSE:AVO - News) -- on the FDA approval front.

"We expect late 2003, early 2004 approval (for Staar)," Mr. Rauch said.

Other possible strengths for the implantable lenses could be that many people with thin corneas are advised against getting Lasik surgery, and could be an untapped market, he added.

Mr. Rauch doesn`t own shares in Staar, and Adams Harkness may seek investment- banking business with the company within 12 months.

He added that the good news for Staar won`t necessarily hurt competitors, though, because it`s "too early."

Lasik surgery, which uses a laser to treat myopia, is patented by Visx Inc. (NYSE:EYE - News) , which licenses its patents to several other companies. Bausch & Lomb Inc.`s (BOL) makes some instruments for the surgery, and LCA-Vision Inc. (NasdaqNM:LCAV - News) operates vision correction centers where the surgery is done.

-Tiffany Kary, Dow Jones Newswires; 201-938-5285; Tiffany.Kary@dowjones.com
Avatar
19.06.03 22:52:20
Hallo,

hat denn niemand hier in Deutschland "Staar" in seinem Depot? :(

Predo
Avatar
15.07.03 21:32:49
Guten Tag,

bin bei Staar bei 2,65 eingestiegen und bin derzeit wirklich zufrieden damit. Ich werde sie auch im Moment nicht mehr hergeben.
Weiß den schon jemand wie demnächst die Zahlen ausfallen werden???
Avatar
20.08.03 00:40:07
hallo, habe auch staa im depot :D :D :D :D
welchen kurzziel hält ihr für real ??
ich denke die 20 $ müsste doch machbar sein oder ? :confused:
Avatar
22.08.08 20:06:37
:look:
Avatar
25.08.08 04:13:02
:eek: Mensch das waren noch Zeiten damals...aber ich glaube jetzt könnte die Zeit von STAAR Surgical endlich gekommen sein! Also ich bin bereits eingestiegen, der Allzeit-Chart sieht für mich ziemlich vielversprechend aus bei den guten Aussichten. Ich will natürlich nicht pushen :laugh: aber vielleicht ist ja noch jemand drin und wir können hier etwas über die Aktie und deren Aussichten plaudern? :p

Aktuell steht STAA bei $5,24



PS: Danke fürs Freischalten SkyMod! :)


Beitrag zu dieser Diskussion schreiben


Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
hier
eine neue Diskussion.